These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35843016)

  • 1. Fenfluramine treatment for dravet syndrome: Real-world benefits on quality of life from the caregiver perspective.
    Jensen MP; Gammaitoni AR; Galer BS; Salem R; Wilkie D; Amtmann D
    Epilepsy Res; 2022 Sep; 185():106976. PubMed ID: 35843016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenfluramine treatment for Dravet syndrome: Caregiver- and clinician-reported benefits on the quality of life of patients, caregivers, and families living in Germany, Spain, Italy, and the United Kingdom.
    Jensen MP; Gammaitoni AR; Salem R; Wilkie D; Lothe A; Amtmann D
    Epilepsy Res; 2023 Feb; 190():107091. PubMed ID: 36701932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany.
    Strzelczyk A; Pringsheim M; Mayer T; Polster T; Klotz KA; Muhle H; Alber M; Trollmann R; Spors H; Kluger G; Kurlemann G; Schubert-Bast S
    Epilepsia; 2021 Oct; 62(10):2518-2527. PubMed ID: 34378197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
    Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
    Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment.
    Bishop KI; Isquith PK; Gioia GA; Knupp KG; Scheffer IE; Nabbout R; Specchio N; Sullivan J; Auvin S; Helen Cross J; Guerrini R; Farfel G; Galer BS; Gammaitoni AR
    Epilepsy Behav; 2023 Jan; 138():108994. PubMed ID: 36463826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis.
    Sullivan J; Specchio N; Devinsky O; Auvin S; Perry MS; Strzelczyk A; Gil-Nagel A; Dai D; Galer BS; Gammaitoni AR
    Epilepsia; 2022 Jan; 63(1):130-138. PubMed ID: 34676542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice.
    Wirrell EC; Lagae L; Scheffer IE; Cross JH; Specchio N; Strzelczyk A
    Epilepsia Open; 2024 Oct; 9(5):1643-1657. PubMed ID: 38962968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study.
    Specchio N; Pietrafusa N; Doccini V; Trivisano M; Darra F; Ragona F; Cossu A; Spolverato S; Battaglia D; Quintiliani M; Luigia Gambardella M; Rosati A; Mei D; Granata T; Dalla Bernardina B; Vigevano F; Guerrini R
    Epilepsia; 2020 Nov; 61(11):2405-2414. PubMed ID: 32945537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and content validation of a preliminary core set of patient- and caregiver-relevant outcomes for inclusion in a potential composite endpoint for Dravet Syndrome.
    Nabbout R; Auvin S; Chiron C; Irwin J; Mistry A; Bonner N; Williamson N; Bennett B
    Epilepsy Behav; 2018 Jan; 78():232-242. PubMed ID: 29108913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
    Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
    Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder.
    Devinsky O; King L; Schwartz D; Conway E; Price D
    Epilepsia; 2021 Jul; 62(7):e98-e102. PubMed ID: 33979451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real-world study.
    Gjerulfsen CE; Nikanorova M; Olofsson K; Johannessen Landmark C; Rubboli G; Møller RS
    Epilepsia Open; 2024 Oct; 9(5):1891-1900. PubMed ID: 39140199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.
    Frampton JE
    Drugs; 2023 Jul; 83(10):923-934. PubMed ID: 37316680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What have we learned from the real-world efficacy of FFA in DS and LGS? A post-marketing study in clinical practice.
    Valls Carbó A; Beltrán Á; Sánchez-Miranda Román I; Cabal B; Gómez-Porro P; Aledo-Serrano Á; López Sobrino G; Ayuga F; Gómez Eguilaz M; Gil-Nagel A
    Epilepsy Behav; 2024 Feb; 151():109620. PubMed ID: 38194770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient and Caregiver Health State Utilities in Lennox-Gastaut Syndrome and Dravet Syndrome.
    Lo SH; Lloyd A; Marshall J; Vyas K
    Clin Ther; 2021 Nov; 43(11):1861-1876.e16. PubMed ID: 34774333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome.
    Cha J; Filatov G; Smith SJ; Gammaitoni AR; Lothe A; Reeder T
    Epilepsia Open; 2024 Feb; 9(1):300-313. PubMed ID: 38018342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.
    Strzelczyk A; Schubert-Bast S
    CNS Drugs; 2022 Mar; 36(3):217-237. PubMed ID: 35156171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive scoping review of fenfluramine's role in managing generalized tonic-clonic seizures in developmental and epileptic encephalopathies.
    Gil-Nagel A; Cross JH; Devinsky O; Ceulemans B; Lagae L; Knupp K; Schoonjans AS; Ryvlin P; Thiele EA; Polega S; Lothe A; Nabbout R
    Epilepsia; 2024 Aug; 65(8):2186-2199. PubMed ID: 39030735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The direct and indirect costs of Dravet Syndrome.
    Whittington MD; Knupp KG; Vanderveen G; Kim C; Gammaitoni A; Campbell JD
    Epilepsy Behav; 2018 Mar; 80():109-113. PubMed ID: 29414539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden.
    Malmberg C; Värendh M; Berling P; Charokopou M; Eklund E
    Appl Health Econ Health Policy; 2024 Jul; 22(4):543-554. PubMed ID: 38758509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.